Our business strategy is to do what we do best — develop our AAV gene therapy and ZFP genome editing technology platforms through research, preclinical and early stage clinical testing. We then look for partners to help us fully realize the value of certain programs through late stage clinical trials and commercialization.
Our plan is to partner certain programs at points of value inflection. In early 2014, we established a collaboration with Biogen Inc. to develop a ZFP Therapeutic approach for beta-thalassemia and sickle cell disease. In early 2012, we established a collaboration with Shire International GmbH (which was amended in September 2015) to develop ZFP Therapeutics for Huntington's disease and one additional gene target.
To contact our Business Development team, please email Curt Herberts, Vice President, Corporate Development at: firstname.lastname@example.org